Immutep not only leads the way with its LAG-3 research but sets the research standard because it was discovered by its Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. This alone has put Immutep as a global leader of immunotherapy drugs for cancer and autoimmune diseases.
“It’s really what we do. We are a LAG-3 company. We have more programs built around LAG-3 than even anyone, including in the Pharma space,” said Immutep CEO Marc Voigt. “The reality is, there has not been a new, approved or validated checkpoint in the past six years. LAG-3 is our opportunity to be the next big thing in immunization technology.”
Some pretty confident statements made there
Interesting read, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.3¢ |
Change
-0.003(0.63%) |
Mkt cap ! $573.7M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.8¢ | 39.0¢ | $1.535M | 3.911M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 54172 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 139580 | 31 |
View Market Depth
| Last trade - 13.21pm 06/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |